QC
CAPR icon

Quadrature Capital’s Capricor Therapeutics CAPR Stock Holding History

Quadrature Capital’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,900
Closed -$240K – 1631
2026
Q1 		$240K Buy
+7,900
New +$210K ﹤0.01% 1057
2025
Q2 		– Sell
-18,899
Closed -$179K – 1082
2025
Q1 		$179K Buy
+18,899
New +$262K ﹤0.01% 872

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Quadrature Capital's CAPR Position: Q2 2026 in Review

Quadrature Capital sold out of Capricor Therapeutics (CAPR) in Q2 2026, closing a stake of 7,900 shares — an estimated $240K sold.

Quadrature Capital first reported a position in CAPR in Q1 2025 and held it in 2 quarters. The position peaked at $240K in Q1 2026. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Quadrature Capital reported no remaining Capricor Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrature Capital sold 7,900 Capricor Therapeutics shares in Q2 2026, an estimated $240K.
  • Quadrature Capital first reported a position in Capricor Therapeutics in Q1 2025 and held it in 2 quarters.
  • Quadrature Capital's Capricor Therapeutics position peaked at $240K in Q1 2026.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.